Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet (PREFERENCE)

Lilly

Status and phase

Completed

Phase 4

Conditions

Schizophrenia

Treatments

Drug: olanzapine therapy

Study type

Interventional

Funder types

Industry

Identifiers

NCT00324051

10960

F1D-VI-S067 (Other Identifier)

Details and patient eligibility

About

The purpose of the study is to estimate drug preference of stable schizophrenic patients who will be treated with olanzapine orodispersible tablets for 6 weeks then with olanzapine tablets for 6 weeks and vice-versa.

Enrollment

284 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

You are an outpatient diagnosed with stable schizophrenia.
You are a male or female in the age of 18 to 65 years old.
You are retrospectively judged by investigators, based on clinical interview and impression, to have been stable for at least 4 weeks.
You must be able to take olanzapine orodispersible in a single daily dose.
You are treated with conventional oral olanzapine tablet (as monotherapy) for at least 1 month.

Exclusion criteria

You have used olanzapine in the past and are no longer using it because of a bad reaction.
You have known Human immunodeficiency virus positive (HIV+) status.
You have known uncorrected, narrow angle glaucoma.
You have known Leukopenia, (abnormally low white blood cell count).
You have a serious or uncontrolled illness (for example: liver disease, history of heart disease, or inadequately controlled diabetes.)
You have Parkinson's disease.
You are a female patient who is either pregnant or nursing
You are taking medications that are not allowed in the study.